CAR T-cell therapy has revolutionized the treatment of certain hematologic malignancies, providing durable remissions for patients who once had few options. Understandably, both patients and oncology ...

The FDA has approved the use of subcutaneous amivantamab and hyaluronidase-lpuj (Rybrevant Faspro) for use in all approved ...

Hormone replacement therapy (HRT) does not have an adverse effect on breast cancer risk, according to findings from an ...

Young, Empowered, and Strong (YES), a mobile health intervention, was linked to improved general and cancer-specific ...

The FDA has granted standard approval to rucaparib (Rubraca) for the treatment of patients with metastatic ...

Onc Nurse On Call is the new podcast by Oncology Nursing News, hosted by editors-in-chief Patricia Jakel, MN, RN, AOCN, and ...

Six-month complete response with frontline axicabtagene ciloleucel predicts long-term survival in patients with high-risk ...

Race was identified as an independent prognostic factor in patients with AML receiving intensive chemotherapy.

Transitioning the dose of axatilimab (Niktimvo) from 0.3 mg/kg every 2 weeks to 0.6 mg/kg every 4 weeks appeared feasible in ...

Combining azacitidine with venetoclax (Venclexta) significantly increased event-free survival (EFS) vs intensive induction ...

Removing total body irradiation (TBI) from conditioning did not degrade efficacy in pediatric and young adult patients with B ...

The use of sacituzumab govitecan to treat HR+/HER2– metastatic breast cancer did not reach its primary end point of ...